Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleThe State of the Art

The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation

Andrea K. Miyahira and Howard R. Soule
Journal of Nuclear Medicine March 2022, 63 (3) 331-338; DOI: https://doi.org/10.2967/jnumed.121.262997
Andrea K. Miyahira
Science Department, Prostate Cancer Foundation, Santa Monica, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Howard R. Soule
Science Department, Prostate Cancer Foundation, Santa Monica, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Timeline of major milestones in development of PSMA theranostics. Research achievements that were supported by PCF funding are indicated by blue font and PCF logo. Dates typically denote year of publication.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (3)
Journal of Nuclear Medicine
Vol. 63, Issue 3
March 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
Andrea K. Miyahira, Howard R. Soule
Journal of Nuclear Medicine Mar 2022, 63 (3) 331-338; DOI: 10.2967/jnumed.121.262997

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation
Andrea K. Miyahira, Howard R. Soule
Journal of Nuclear Medicine Mar 2022, 63 (3) 331-338; DOI: 10.2967/jnumed.121.262997
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • BIRTH: DISCOVERY AND EARLY CHARACTERIZATION
    • YOUTH: EARLY EVIDENCE OF UTILITY
    • ADOLESCENCE: TRANSLATION
    • ADULT: THERANOSTICS REVOLUTION
    • THE CORNERSTONE ROLE OF PCF IN PSMA THERANOSTICS
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • A 2022 International Survey on the Status of Prostate Cancer Theranostics
  • Google Scholar

More in this TOC Section

  • A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and Industry
  • Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
  • Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better
Show more The State of the Art

Similar Articles

Keywords

  • theranostics
  • prostate cancer
  • PSMA
  • PET imaging
  • molecular radiotherapy
SNMMI

© 2025 SNMMI

Powered by HighWire